Linda Bain, Chief Financial Officer at Avalanche Biotechnologies, Inc. ([AAVL]), sold 3,500 shares at $39.94 ($140K) on 2015-06-12, disclosed to the SEC on 2015-06-15.
Scheduled sale ($140k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CDAK | SELL | 2023-01-23 | $1K | — | Filing → |
| [AAVL] | SELL | 2015-05-13 | $10K | — | Filing → |
| [AAVL] | SELL | 2015-05-12 | $25K | — | Filing → |